(Source: Enanta Pharmaceuticals Inc) AbbVie’s ongoing TOPAZ-II study evaluates long-term treatment outcomes in genotype 1a and genotype 1b chronic HCV patients with or without compensated cirrhosis Patients treated with VIEKIRA PAK, with or without ribavirin, achieved 95 percent sustained virologic response rates at 12 weeks post-treatment (SVR 12 ) VIEKIRA PAK contains Enanta’s lead protease inhibitor, Paritaprevir WATERTOWN, Mass.--(BUSINESS WIRE)--Nov. 14, 2015-- Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data from AbbVie’s...
↧